Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
AIMS: Aortic stenosis (AS) is associated with significant morbidity and mortality. Recombinant apolipoprotein A-I Milano (rApoA-I(M)) induces atherosclerotic plaque regression. The aims of this study were to determine the effects of rApoA-I(M) on experimental aortic valve degeneration and its mechanisms of action. METHODS AND RESULTS: New Zealand White rabbits (n = 20) were fed an atherogenic diet for 9 months and then randomized to either placebo or rApoA-I(M). Echocardiography was used to assess the effect of the treatments on AS. Porcine aortic valve myofibroblasts (PAVMF) treated with oxidized low-density lipoprotein served to define the effects of rApoA-I(M) on the expression of monocyte chemoattractant protein-1 (MCP-1), nuclear factor (NF)-kappaB, and alkaline phosphatase (AP). Recombinant apolipoprotein A-I Milano increased aortic valve area (AVA) by 32% (0.25 +/- 0.05 to 0.34 +/- 0.07 cm(2), P < 0.01); whereas AVA remained unchanged in the placebo group (0.24 +/- 0.05 to 0.26 +/- 0.04 cm(2), P = 0.58). Histopathological examination of aortic valves in the rApoA-I(M) animals showed significantly less leaflet thickening, inflammation, and calcification vs. the placebo group. In vitro, rApoA-I(M) significantly inhibited MCP-1, AP, and NF-kappaB and decreased intracellular cholesterol content in PAVMF. CONCLUSION: Recombinant apolipoprotein A-I Milano treatment reverses AS in this experimental rabbit model. The beneficial effects seem to be mediated by enhanced cholesterol removal and by reduced inflammation and calcification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burden of valvular heart diseases: a population-based study
Nkomo, V. T., Gardin, J. M., Skelton, T. N., Gottdiener, J. S., Scott, C. G., & Enriquez-Sarano, M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69208-8 · Cited by 4,881 · cited 2×
“Aortic valve stenosis (AS) is the second most common indication for adult heart surgery in the USA.1 Without surgical correction, symptomatic severe AS is associated with high morbidity and dismal survival.2 Moreover, the elderly patients plagued with symptomatic severe AS are often precluded from surgical options.3 A…”
BackgroundClinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029 · cited 1×
“Epidemiological data have associated fibrocalcific AS with several cardiovascular risk factors such as advanced age, male gender, hypertension, diabetes, smoking, and elevated lowdensity lipoprotein (LDL) cholesterol.(4,5) In fact, several studies”
BackgroundNissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644 · cited 3×
“17 To date, randomized trials of statin therapy have shown no benefit in slowing AS progression.(14,15) However, the timing of statin therapy in relation to the severity of the disease has been hypothesized to be of great importance.”
BackgroundResultA Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043876 · Cited by 1,146 · cited 3×
“17 To date, randomized trials of statin therapy have shown no benefit in slowing AS progression.(14,15) However, the timing of statin therapy in relation to the severity of the disease has been hypothesized to be of great importance.”
BackgroundResultDecision-making in elderly patients with severe aortic stenosis: why are so many denied surgery?
Iung, B., Cachier, A., Baron, G., Messika-Zeitoun, D., Delahaye, F., Tornos, P., Gohlke-Bärwolf, C., Boersma, E., Ravaud, P., & Vahanian, A. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi471 · Cited by 1,108 · cited 1×
“Moreover, the elderly patients plagued with symptomatic severe AS are often precluded from surgical options.(3) As such, pharmacological interventions capable of slowing or preventing the progression of AS are desperately needed.”
BackgroundO’Brien, K. D., Reichenbach, D. D., Marcovina, S. M., Kuusisto, J., Alpers, C. E., & Otto, C. M. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.4.523 · Cited by 560
Cited by
Colchicine—Update on mechanisms of action and therapeutic uses
Leung, Y. Y., Yao Hui, L. L., & Kraus, V. B. (2015) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2015.06.013 · Cited by 950
Calcific Aortic Valve Stenosis: Methods, Models, and Mechanisms
Miller, J. D., Weiss, R. M., & Heistad, D. D. (2011) · Circulation Research · doi:10.1161/circresaha.110.234138 · Cited by 323
The effect of statins on valve function and calcification in aortic stenosis: a meta-analysis
Zhao, Y., Nicoll, R., He, Y. H., & Henein, M. Y. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.023 · Cited by 80
Li, F., Cai, Z., Chen, F., Shi, X., Zhang, Q., Chen, S., Shi, J., Wang, D. W., & Dong, N. (2012) · Basic Research in Cardiology · doi:10.1007/s00395-012-0306-0 · Cited by 67
“MCP-1 has also been associated with macrophages infiltration in a rabbit model of AV calcification model [42].”
BackgroundMethodApoC-III is a novel inducer of calcification in human aortic valves
Schlotter, F., de Freitas, R. C. C., Rogers, M. A., Blaser, M. C., Wu, P.-J., Higashi, H., Halu, A., Iqbal, F., Andraski, A. B., Rodia, C. N., et al. (2021) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015700 · Cited by 49
“Lowdensity lipoprotein cholesterol (LDL-C), oxidized phospholipids, and triglycerides are associated with onset of CAVD (10, 14, 15) and are introduced into the valvular matrix as components of lipoproteins.”
Background
Metadata
- Authors
- Speidl, W. S., Cimmino, G., Ibanez, B., Elmariah, S., Hutter, R., Garcia, M. J., Fuster, V., Goldman, M. E., & Badimon, J. J.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-03-19
- Volume
- 31
- Issue
- 16
- Pages
- 2049-2057
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2095808083
- Cited by
- 60
- References
- 7
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. https://app.cochat.ai/papers/10.1093/eurheartj/ehq064
- The paper
- Speidl, W. S., Cimmino, G., Ibanez, B., Elmariah, S., Hutter, R., Garcia, M. J., Fuster, V., Goldman, M. E., & Badimon, J. J. (2010). Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. European Heart Journal. https://doi.org/10.1093/eurheartj/ehq064
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.